Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ultrasound Microbubble Destruction and Perfusion Quantification for Improving Radioembolization Therapy of Hepatocellular Carcinoma

Trial Profile

Ultrasound Microbubble Destruction and Perfusion Quantification for Improving Radioembolization Therapy of Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs Perflutren (Primary) ; Yttrium-90
  • Indications Liver cancer
  • Focus Diagnostic use; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2018 Planned number of patients changed from 40 to 52.
    • 03 Jan 2018 Planned number of patients changed from 52 to 40.
    • 19 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top